FDA gives Lupin tentative nod for generic Lumify
Brimonidine Tartrate Ophthalmic Solution is indicated to relieve redness of the eye due to minor eye irritations.
Lupin has received tentative approval from the Food and Drug Administration for Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC), which is a generic of Bausch & Lomb's Lumify.
Brimonidine Tartrate Ophthalmic Solution, 0.025%(OTC) is indicated to relieve redness of the eye due to minor eye irritations.
[Read more: Lupin receives FDA OK for generic Banzel]
This product will be manufactured at Lupin’s Pithampur facility in India.
Brimonidine Tartrate Ophthalmic Solution (RLD Lumify) had a market value of $39 million, per IQVIA June 2024 data.
[Read more: Lupin receives FDA nod for 3 generics]